TL;DR — Ashwagandha root extract is the best-evidenced adaptogen for perceived stress, anxiety symptoms, and self-reported sleep quality, anchored by a 60-day RCT showing a 27.9% serum-cortisol drop and a 2022 meta-analysis of 12 RCTs (n=1,002) confirming the anxiety/stress effect. A separate 8-week RCT also found real strength and testosterone gains in resistance-trained men. The genuine caution: a growing case-series literature (Iceland/US DILIN, five patients) documents idiosyncratic cholestatic liver injury, almost always self-limited but occasionally severe — this is not a "no downside" botanical.
Overview & the withanolide/HPA-axis mechanism
Ashwagandha (Withania somnifera, also called Indian ginseng or winter cherry) is a root extract used in Ayurvedic medicine for millennia, but its modern clinical case rests on a narrower and more testable claim than "adaptogen": standardized root extracts measurably blunt the hypothalamic-pituitary-adrenal (HPA) axis stress response and lower circulating cortisol in chronically stressed adults. That reframing — from vague tonic to a specific, dose-anchored, cortisol-lowering intervention — is what separates ashwagandha's evidence base from most traditional botanicals on this site.
Primary hallmarks targeted: Chronic inflammation · Altered intercellular communication
Chandrasekhar et al. 2012 (PMID 23439798, Indian Journal of Psychological Medicine 34(3):255–262): a 60-day, double-blind RCT randomized 64 adults with a history of chronic stress to 300 mg BID of a high-concentration full-spectrum ashwagandha root extract or placebo. The treatment group showed significant reductions across all stress-assessment scales (P<0.0001) and a mean serum cortisol reduction of roughly 28% versus placebo, with no serious adverse events. Akhgarjand et al. 2022 (PMID 36017529, Phytotherapy Research 36(11):4115–4124), a meta-analysis of 12 RCTs (n=1,002), confirmed significant pooled reductions in both anxiety (SMD −1.55) and perceived stress (SMD −1.75), while flagging high between-study heterogeneity — different extracts, doses, and populations are being pooled together.
Mechanism — GABA-mimetic action, HPA-axis, and a secondary anti-inflammatory route
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| GABA-mimetic / GABA-A modulation | Withanolides (withanolide A, withaferin A) bind GABA-A receptor sites, producing anxiolytic-like effects in preclinical models | Altered intercellular communication |
| HPA-axis dampening | Blunts the cortisol surge to acute and chronic stressors, the best human-validated mechanism | Altered intercellular communication |
| NF-κB / cytokine suppression | Withaferin A inhibits NF-κB signaling in vitro, reducing downstream inflammatory cytokines | Chronic inflammation |
| Androgen/anabolic signaling | Resistance-training RCT found significant testosterone increases alongside strength gains — mechanism not fully isolated from stress-hormone reduction | Altered intercellular communication |
Unlike a single-receptor drug, ashwagandha's effects converge on the HPA axis from multiple withanolide-driven inputs — this is why the human trials measuring cortisol and validated stress scales are more informative than any single in-vitro mechanism paper.
When ashwagandha is worth your money
Ashwagandha earns a place when two or more apply:
- You have measurable, chronic (not acute-crisis) perceived stress or mild-to-moderate anxiety symptoms
- Poor or non-restorative sleep is a target you can track (sleep diary, actigraphy, or a validated questionnaire)
- You are resistance training and want an adjunct with real strength-trial support, not just a stress claim
Skip or defer if you have any pre-existing liver disease, are pregnant, have a diagnosed thyroid condition, or would not commit to baseline-and-follow-up liver enzyme monitoring given the case-report signal in Section 6.
Evidence summary — stress, sleep, and strength are three separate claims
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Chandrasekhar 2012 (PMID 23439798) | RCT vs placebo | 64 | 60 days | ↓Stress-scale scores (P<0.0001); ~28% ↓serum cortisol | B |
| Akhgarjand 2022 meta-analysis (PMID 36017529) | Meta-analysis, 12 RCTs | 1,002 | ≤12 wk | Pooled ↓anxiety (SMD −1.55), ↓stress (SMD −1.75); high heterogeneity | B |
| Langade 2020 (PMID 32540634) | RCT vs placebo, healthy adults | 150 | 6 wk | 120 mg/day (Shoden) → 72% self-reported sleep-quality improvement vs 29% placebo | B |
| Wankhede 2015 (PMID 26609282) | RCT vs placebo, resistance-trained men | 57 | 8 wk | 300 mg BID → greater bench-press/leg-extension strength, muscle size, and testosterone gains vs placebo | B |
| Björnsson 2020 (PMID 31991029) | Case series, DILIN + Iceland | 5 | — | Cholestatic/mixed liver injury; 4/5 normalized in 1–5 months, none fatal in this series | Safety signal |
← Swipe for more columns →
Consensus: Tier B. What we know: the stress/anxiety/cortisol claim is the most repeated and best human-validated effect, sleep-quality data is a real but single-trial-anchored signal (mostly tied to the Shoden 120 mg formulation), and the strength/testosterone finding is a genuine RCT result that has not been broadly replicated at scale. What we don't know: there is no human longevity or hard-outcome trial — the hallmark linkage (inflammation, cell communication) is inferred from cortisol/cytokine mechanism, not demonstrated as a healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary → effect.
Where ashwagandha disappoints
- It's a stress/sleep tool, not a longevity one. The evidence is for perceived stress, anxiety, and cortisol — the anti-aging framing is inferred from mechanism, with no healthspan trial behind it. - Formulation and goal are specific. A stress-anchored 600 mg extract isn't automatically a sleep-optimized dose (that's the 120 mg Shoden form); the meta-analysis pools very different products (high heterogeneity), so results don't transfer neatly. - It carries a real liver signal. Published cholestatic liver-injury cases mean this is genuinely "not a no-downside botanical" — a caveat most adaptogen marketing omits.
Should you start ashwagandha?
Is your primary goal reducing perceived stress, anxiety symptoms, or poor sleep?
Start a standardized extract (KSM-66 or Shoden) at the trial-anchored dose; reassess with a validated stress/sleep scale at 8–12 weeks
node | Are you resistance training and want an adjunct with real strength-trial support?
Consider the Wankhede 2015 protocol (300 mg BID) alongside training; reassess strength/composition at 8 weeks
The remaining longevity case is mechanistic (cortisol/inflammation) — treat as speculative, not a settled healthspan lever
Any liver disease or unexplained elevated liver enzymes, pregnancy, thyroid disorder, or scheduled surgery — obtain physician clearance before starting
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose (stress/anxiety) | 300 mg BID (600 mg/day) standardized root extract, ≥5% withanolides | Chandrasekhar 2012 dose |
| Dose (sleep-specific) | 120 mg/day, higher-concentration extract (Shoden-type) | Langade 2020 dose; a distinct, more concentrated form |
| Dose (strength adjunct) | 300 mg BID alongside a resistance-training program | Wankhede 2015 dose |
| Timing | AM/PM split for stress dosing; PM for sleep-only use | Match the trial it's anchored to |
| Duration | 8–12 weeks before judging | Matches the RCT windows above |
Week-one compliance checklist
- [ ] Confirm the label states standardization (KSM-66 5% withanolides, or Shoden) — unstandardized "ashwagandha powder" is not equivalent to trial material
- [ ] Record baseline perceived-stress score (e.g., PSS-10), sleep quality, or strength numbers before dose one
- [ ] Get baseline liver enzymes (ALT/AST) if starting for the first time or stacking with other hepatically-cleared supplements
- [ ] Note any thyroid medication — ashwagandha has reported mild thyroid-stimulating effects
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Perceived Stress Scale (PSS-10) or similar | Trending down | Baseline, 8–12 wk | No change → reassess whether stress is genuinely the rate-limiter |
| Sleep quality (diary or questionnaire) | Trending toward restorative | Baseline, 6 wk | No change → consider the higher-concentration (Shoden) form specifically |
| ALT / AST (liver enzymes) | Normal range | Baseline, 8–12 wk, or sooner if symptomatic | Elevated, jaundice, or pruritus → stop immediately and seek medical evaluation |
| TSH (if on thyroid medication) | Stable, within therapeutic range | Baseline, 8–12 wk | Drifting → discuss with prescriber before continuing |
← Swipe for more columns →
Perceived stress (PSS-10)
Elevated
Serum cortisol
Elevated/high-normal
Sleep quality (self-reported)
Non-restorative
Perceived stress (PSS-10)
Meaningfully reduced
Serum cortisol
Modest reduction
Sleep quality (self-reported)
Improved, especially on Shoden-type extract
Safety, red flags, and contraindications
- Generally well tolerated in trials — the RCTs above report mild GI upset and drowsiness as the most common adverse effects, with no serious events at trial doses.
- Case reports, not just theoretical risk — this is a documented, published safety signal, not a hypothetical caution.
Liver injury is a real, published signal — not marketing caution language
- Cholestatic/mixed liver injury — Björnsson et al. 2020 (PMID 31991029) documented five cases (Iceland + US DILIN registry) with jaundice and pruritus onset 2 weeks to several months after starting ashwagandha; most normalized within 1–5 months after stopping, but injury was clinically significant in all five and other published case reports describe more severe courses.
- Avoid with any pre-existing liver disease — do not self-start if you have cirrhosis, hepatitis, or unexplained elevated liver enzymes.
- Thyroid-stimulating effect — ashwagandha has been reported to raise T3/T4; use caution or avoid if you have hyperthyroidism or are on thyroid medication.
- Pregnancy — traditionally used as an abortifacient in high doses; avoid entirely.
- Sedative interaction — additive drowsiness with benzodiazepines, sedatives, or alcohol.
- Consult a physician before starting if you take thyroid medication, immunosuppressants, or sedative/hypnotic medications.
- Stop and seek medical evaluation for jaundice, dark urine, unusual fatigue, or right-upper-quadrant pain at any point during use.
What would change this grade. Ashwagandha is B — well-supported for stress/anxiety, unproven for longevity. A human healthspan trial would be needed to extend it beyond the stress claim; the liver-injury signal also caps enthusiasm. Broader independent replication of the strength/testosterone result would firm up that secondary use.
Who should skip ashwagandha
- Any pre-existing liver disease or unexplained elevated liver enzymes — the cholestatic-injury signal applies directly; don't self-start. - Pregnancy (traditional abortifacient) or a thyroid disorder / thyroid medication — real reproductive and T3/T4 effects. - Anyone on sedatives, benzodiazepines, or regular alcohol — additive drowsiness.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Magnesium | Complementary calming/HPA-relevant mineral cofactor; overlapping sleep-support use case | Magnesium module |
| Rhodiola | Both are adaptogens acting on stress physiology, but rhodiola leans stimulating/fatigue-directed while ashwagandha leans calming — evaluate as complementary, not redundant | Rhodiola module |
| Melatonin | Distinct sleep-onset mechanism (circadian receptor binding vs cortisol dampening); reasonable to combine for sleep-specific goals | Melatonin module |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Sedatives / benzodiazepines / alcohol | Additive drowsiness and CNS depression | Don't combine before anything needing alertness |
| Thyroid medication | Ashwagandha can raise T3/T4, destabilizing a managed dose | Monitor TSH; coordinate with your prescriber |
| Other hepatotoxic supplements (e.g. high-dose EGCG) | Stacking liver-signal compounds compounds the risk | Don't co-run; monitor ALT/AST if you must |
Personal results template
My Ashwagandha results log
| Date | Week | Dose / form | PSS-10 | Sleep quality (1–10) | ALT/AST | Notes |
|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | Baseline |
| YYYY-MM-DD | 6 | 120 mg (Shoden) or 300 mg BID | — | — | — | Sleep or stress checkpoint |
| YYYY-MM-DD | 12 | — | — | — | — | Primary endpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: PSS-10 or sleep quality trending down/up respectively, with normal liver enzymes. - No effect: No measurable movement at 12 weeks with confirmed compliance — reassess whether the extract form or dose matched the trial it's anchored to. - Stop and reassess: Jaundice, dark urine, unusual fatigue, or any liver-enzyme elevation — stop immediately and seek medical evaluation.
Log your experiment
Ashwagandha's evidence is formulation- and goal-specific — track it against a defined baseline so you can tell a real cortisol/stress response from placebo.
Personal journeyReferences
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.